<DOC>
	<DOCNO>NCT02741518</DOCNO>
	<brief_summary>This randomize control pilot study assess microbiological clinical impact Fecal Microbiota Transplantation ( FMT ) patient obesity . The investigator prospectively enroll 20 adult patient obese ( Body Mass Index 35kg/m2 high ) provide write informed consent . The study participant randomize 1:1 either treatment arm placebo arm . The treatment arm receive induction FMT capsule follow monthly maintenance dose oral capsule 12 week total . The placebo group receive placebo capsule induction follow monthly intake oral placebo capsule 12 week .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Treatment Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>1 . Age 18 year old 2 . Obesity define BMI 35kg/m2 high 1 . Triglycerides &gt; 500 mg/dL 2 . Use antibiotic &lt; 8 week prior participation 3 . Use probiotic &lt; 4 week prior participation 4 . Alcohol use great 20g/daily suspicion alcohol abuse dependence 5 . Substance abuse , current 6 . LFTS great 3x ULN 7 . Cirrhosis . 8 . DM type 2 insulin dependent , treated GLP1agonists , poorly control oral medication ( HbA1C &gt; 10 % ) 9 . Use weight loss medication participation weight loss study program Weight Watchers 10 . History recent weight change ( weight loss weight gain two month precede trial enrollment ) . This defined gain loss 10 pound precede 2 month 11 . Patients pregnant breastfeed 12 . Patients unable give inform consent 14 . Patients previously undergone FMT 15 . Patients confirm malignancy cancer 16 . Patients immunocompromised 17 . Participation clinical trial precede 30 day simultaneously trial 18 . Previous gastric small intestinal surgery alters gut anatomy fundoplication , gastric resection , gastric bypass , small bowel resection , ileocectomy 19 . Other comorbidities include : systemic lupus , inflammatory bowel disease , Chronic kidney disease define GFR &lt; 60mL/min/1.73m2 44 20 . History rheumatic heart disease , endocarditis , valvular disease due risk bacteremia 21 . Any condition , base clinical judgment may make study participation unsafe 22 . History severe food allergy 23 . Use immune modulators include methotrexate , mycophenolate mofetil , tacrolimus , cyclosporine , thalidomide , Interleukin10 , Interleukin11 24.Treatment infliximab , adalimumab , certolizumab , natalizumab , vedolizumab thalidomide 25 . Congenital acquire immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>FMT</keyword>
</DOC>